# Eplerenone (Inspra) *Also known as: Eplerenone, Inspra* Eplerenone comes up in bodybuilding discussions for water retention, blood pressure and hoped-for heart or kidney protection during steroid use. Its specific action is blocking aldosterone, a hormone involved in salt balance. The practical trade-off is potassium: it can rise, especially when other cardiovascular medicines are involved. Educational information only — not medical advice. Modelled values are not individual measurements or dosing recommendations. ## Dosage & duration US Inspra label · adult starting treatment depends on the indication ### Post-heart-attack HFrEF **Product label** - **Dose:** 25 mg per dose initially - **How often:** Once daily by mouth - **How long:** Ongoing treatment with laboratory-guided review The label aims toward 50 mg daily within 4 weeks if tolerated; potassium changes can require a different plan. - [DailyMed — Inspra (eplerenone) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a) — US label revised June 2025: adult hypertension and stable post-MI symptomatic HFrEF; indication-specific starting doses, potassium/renal monitoring, CYP3A and potassium-related interactions. Dose proportionality 25–100 mg; timing 3–6 h half-life and 1.5–2 h peak. ### Hypertension **Product label** - **Dose:** 50 mg per dose initially - **How often:** Once daily by mouth - **How long:** Response reassessed over several weeks Higher or split dosing is a clinician decision; renal function, potassium and interacting drugs can change eligibility and dose. - [DailyMed — Inspra (eplerenone) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a) — US label revised June 2025: adult hypertension and stable post-MI symptomatic HFrEF; indication-specific starting doses, potassium/renal monitoring, CYP3A and potassium-related interactions. Dose proportionality 25–100 mg; timing 3–6 h half-life and 1.5–2 h peak. These are named label contexts, not a plan to manage steroid-related water retention. A lower plotted peak does not guarantee safe potassium. Dose-context sources checked: 2026-10-09. ## At a glance - **Why lifters look at it:** Bloat + blood-pressure concerns - **How it is different:** Blocks aldosterone Sources or review notes: [1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a). - **What changes the decision:** Potassium + kidney function Sources or review notes: [1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a). **Catalog evidence label (not clinical review):** Human RCT evidence ## Swelling, blood pressure and potassium - **Identify the cause:** A puffy appearance alone does not explain why fluid is being retained. - **A different hormone target:** Eplerenone blocks aldosterone signaling; it does not replace an aromatase inhibitor. - **Potassium and kidneys:** Potassium can rise, especially with telmisartan, other relevant medicines or potassium products. Benefits in selected heart-failure patients do not establish prevention of steroid-related heart or kidney injury. Visual sources checked: 2026-10-09. - [DailyMed — Inspra (eplerenone) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a) — US label revised June 2025: adult hypertension and stable post-MI symptomatic HFrEF; indication-specific starting doses, potassium/renal monitoring, CYP3A and potassium-related interactions. Dose proportionality 25–100 mg; timing 3–6 h half-life and 1.5–2 h peak. ## Overview ## Why do bodybuilders discuss eplerenone? Some bodybuilders consider it for water retention they attribute to GH or anabolic use, or for cardiovascular concerns alongside medicines such as telmisartan. Some users also compare it with spironolactone because of receptor selectivity. These are the reasons for interest; reported experiences are mixed. ## Is this an estrogen-control drug? No. Eplerenone blocks the action of aldosterone, a hormone involved in salt and fluid balance. An aromatase inhibitor acts on estrogen production. A puffy appearance does not tell you which pathway is responsible, so adding a diuretic is not a substitute for identifying the cause of new swelling. ## How does it compare with telmisartan? Both appear in blood-pressure discussions, but they act at different points: telmisartan blocks an angiotensin receptor, while eplerenone blocks aldosterone signaling. Their combination can increase potassium risk and needs a specific clinical reason and monitoring. Adding another medicine when BP is already low-normal is not automatically extra protection. ## What about preventing steroid heart damage? Eplerenone has clinical outcome evidence in selected heart-failure patients. That does not establish prevention of steroid-related heart or kidney injury in otherwise healthy lifters. Blood-pressure readings are useful, but cannot answer every question about cardiovascular health. ## What is the most useful follow-up? Potassium and kidney-function testing, together with BP readings and a medication review. The label calls for potassium testing before starting, within the first week and at one month after starting or adjusting treatment. Treatment duration depends on the condition being treated. ## Estimated concentration model Oral-tablet concentration estimate **Output:** eplerenone parent: estimated concentration in plasma (ng/mL). Estimated from study endpoints; the curve between measurements is reconstructed. Reconstructs the fasting INSPRA tablet study; it does not predict blood-pressure or potassium response. - **Formulation:** INSPRA 50 mg oral tablet (Pfizer Canada), fasted single dose - **Study population:** 24 healthy adult participants in the monograph bioequivalence analysis - **Route:** Oral One fasting INSPRA 50 mg reference arm: mean terminal half-life 4.56 h and median peak time 1.75 h. - **Calibration dose:** 50 mg - **Reported calibration peak:** 1281.72 ng/mL - **Peak timing used:** 1.75 hours - **Terminal half-life used:** 4.56 hours - **Reconstructed absorption rate:** 1.434773 /hour ### Assumptions and limits - The observed peak already incorporates oral availability; do not multiply by the separately reported 69% bioavailability. - Mean peak and terminal half-life plus median peak timing summarize a population; this is not an individual fitted profile. - Linear dose scaling and dose superposition are approximations. The US label describes dose-proportional exposure at 25–100 mg, not unrestricted proportionality. - Predicted AUC∞ is 11001.69 ng·h/mL, about 9.9% above the reference-arm mean 10009.82; matching peak/timing does not reproduce every exposure metric. - Kidney/liver function, heart failure and CYP3A interactions can change exposure or safety. The model does not choose a potassium threshold, dose or blood-pressure target. ### Model sources - [Health Canada — JAMP Eplerenone monograph, comparative bioavailability](https://pdf.hres.ca/dpd_pm/00073599.PDF) — Page 27 reference INSPRA 50 mg arm, fasting single-dose crossover, 24 healthy adults: arithmetic Cmax 1281.72 ng/mL, median Tmax 1.75 h, arithmetic half-life 4.56 h, arithmetic AUC∞ 10009.82 ng·h/mL. Test-product values and geometric means are not used. - [DailyMed — Inspra (eplerenone) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a) — US label revised June 2025: adult hypertension and stable post-MI symptomatic HFrEF; indication-specific starting doses, potassium/renal monitoring, CYP3A and potassium-related interactions. Dose proportionality 25–100 mg; timing 3–6 h half-life and 1.5–2 h peak. **Revision:** eplerenone-inspra-fasting-estimate-2026-10 · version 1 ## Harm reduction - **Interaction notes:** High potassium and renal-function changes require monitoring. Strong CYP3A inhibitors are contraindicated; additional restrictions depend on the indication. ## Sources and review notes Summary source check: 2026-10-09; see source notes 1. This does not certify medical review of the whole page. ### Notes on the quick facts - **Why lifters look at it:** These are documented discussion topics, not proof that every case of steroid-related swelling has the same cause. Source check: 2026-10-09; not a medical review. - **How it is different:** It acts on salt-balance signaling; it does not replace an aromatase inhibitor for an estrogen-related problem. Source check: 2026-10-09; not a medical review. - **What changes the decision:** Especially relevant when telmisartan, other RAAS medicines or potassium products are already in the picture. Source check: 2026-10-09; not a medical review. ### References 1. [DailyMed — Inspra (eplerenone) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a) — US label revised June 2025: adult hypertension and stable post-MI symptomatic HFrEF; indication-specific starting doses, potassium/renal monitoring, CYP3A and potassium-related interactions. Dose proportionality 25–100 mg; timing 3–6 h half-life and 1.5–2 h peak. 2. [Health Canada — JAMP Eplerenone monograph, comparative bioavailability](https://pdf.hres.ca/dpd_pm/00073599.PDF) — Page 27 reference INSPRA 50 mg arm, fasting single-dose crossover, 24 healthy adults: arithmetic Cmax 1281.72 ng/mL, median Tmax 1.75 h, arithmetic half-life 4.56 h, arithmetic AUC∞ 10009.82 ng·h/mL. Test-product values and geometric means are not used. 3. [NHS — about eplerenone](https://www.nhs.uk/medicines/eplerenone/about-eplerenone/) — Patient-facing explanation of aldosterone blockade, heart-failure treatment and the need for potassium blood tests. --- **Canonical URL:** https://anabolicplotter.com/compounds/eplerenone/ **Methodology:** https://anabolicplotter.com/methodology/ **Plot:** https://anabolicplotter.com/plot?compound=eplerenone